NOVARTIS: Very much in-line set of data in terms of FY 2019 and 2020 guidance | BUY | CHF107(+18%)
NOVARTIS - BUY | CHF107(+18%)Very much in-line set of data in terms of FY 2019 and 2020 guidance
Q4 was as strong as was the full-year 2019
Core EPS of USD1.32 is bang in line with CS estimates
Guidance for 2020 meets expectations too
Little to support material upgrades
Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.